Clinical Trials Sponsored by Bristol-Myers Squibb

Total 2677 results

Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis (FALCON 2)

Nonalcoholic Steatohepatitis | Liver Fibrosis | Nonalcoholic Fatty Liver Disease (NAFLD) | Hepatic Cirrhosis

United States, Japan
Bristol-Myers Squibb

Terminated

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

COVID-19 | SARS-CoV-2

Puerto Rico, United States
Bristol-Myers Squibb

Completed

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (ADVISE)

Advanced Cancer

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies (CheckMate 908)

Various Advanced Cancer

United States, Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, United Kingdom
Bristol-Myers Squibb

Completed

Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

Acute Decompensated Heart Failure

United Kingdom, Israel, Argentina, Czechia, Greece, Poland
Bristol-Myers Squibb

Completed

The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma (CheckMate 800)

Renal Cell Carcinoma

United States, Australia, Chile
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

Squamous Cell Non-small Cell Lung Cancer

United States, Italy, France, Germany
Bristol-Myers Squibb

Completed

Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Chronic Myeloid Leukemia | Philadelphia Chromosome | Chronic Myeloid Leukemia in Chronic Phase

China
Bristol-Myers Squibb

Completed

A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate

Stem Cell Transplantation

United States
Bristol-Myers Squibb

Completed

Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

Thrombosis

United States
Bristol-Myers Squibb

Terminated

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

Healthy Participants

United States
Bristol-Myers Squibb

Withdrawn

Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico

Multiple Indications Cancer

Mexico
Bristol-Myers Squibb

Withdrawn

Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma

Multiple Myeloma

Korea, Republic of
Bristol-Myers Squibb

Withdrawn

Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults

Hepatitis C

Mexico
Bristol-Myers Squibb

Completed

Observational Study for Lung Cancer Patients Treated With Nivolumab (EVIDENS)

Lung Cancer

France
Bristol-Myers Squibb

Completed

A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan

COVID-19

Japan
Bristol-Myers Squibb

Completed

Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

Atrial Fibrillation
Bristol-Myers Squibb

Active, not recruiting

Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy (NICO)

Melanoma

Germany
Bristol-Myers Squibb

No longer available

Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab
Bristol-Myers Squibb

Completed

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer

Head and Neck Cancer

Japan
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab in Patients With Head and Neck Cancer. (ProNiHN)

Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck

France
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986235 in Healthy Subjects

Mediators of Inflammation

United States
Bristol-Myers Squibb

Active, not recruiting

A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France (AdjuMel)

Melanoma

France
Bristol-Myers Squibb

Completed

A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan

Non-Valvular Atrial Fibrillation (NVAF)

Japan
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Venous Thromboembolism (VTE)

United States
Bristol-Myers Squibb

Completed

Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy

Hepatitis C

Japan
Bristol-Myers Squibb

Completed

ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE

Venous Thromboembolism

Japan
Bristol-Myers Squibb

Completed

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Active Psoriatic Arthritis

Spain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

Liver Fibrosis | Hepatic Cirrhosis

United States
Bristol-Myers Squibb

Active, not recruiting

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Melanoma

Australia
Bristol-Myers Squibb

Completed

Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan

Rheumatoid Arthritis

Taiwan
Bristol-Myers Squibb

Completed

A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Taste Properties of Atazanavir and Cobicistat

HIV in Adults

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants

Health Participants

United States
Bristol-Myers Squibb

Approved for marketing

Expanded Access to Nivolumab (Opdivo)

Pediatric Cancer
Bristol-Myers Squibb

Completed

Effect of BMS-986165 on the Blood Levels of Metformin

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Lymphoma. Non-Hodgkin

Germany, Italy, United States, Spain, Netherlands, Australia, United Kingdom, Belgium, France, Canada, Sweden, Singapore
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself (CheckMate204)

Melanoma

United States
Bristol-Myers Squibb

Completed

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function

Renal Failure

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)

Melanoma

Belgium, Brazil, United States, Canada, Spain, Greece, France, United Kingdom, Australia, Italy, Austria, Switzerland, Germany, Israel, Russian Federation, Romania, Czechia, Poland, New Zealand
Bristol-Myers Squibb

Terminated

An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

Leukemia

Taiwan, United States, Brazil, Japan, Italy, Korea, Republic of, Canada, China, Israel, Romania
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Melanoma | Skin Cancer

United States, Canada, Netherlands, Spain, Australia, Italy, Japan, Germany, Ireland, United Kingdom, Czechia, Switzerland, Poland, France, Greece, New Zealand
Bristol-Myers Squibb

Completed

Effects of Abatacept in Patients With Early Rheumatoid Arthritis (AVERT-2)

Rheumatoid Arthritis

Italy, Sweden, Taiwan, United States, Peru, Germany, Mexico, Japan, Israel, Spain, Czechia, Argentina, Brazil, Colombia, Romania, Australia, France, Poland, Singapore, Russian Federation, South Africa, Canada, United Kingdom, Hungary, C... and more
Bristol-Myers Squibb

Completed

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer

Breast Cancer

Japan
Bristol-Myers Squibb

Terminated

Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection

Hepatitis C | Chronic Hepatitis

Australia, Spain

3

Subscribe